Sigilon: Signal: Tweets of the week focus on Eli Lilly's most recent acquisitions
Eli Lilly is enlarging its drug pipeline with major acquisitions following second quarter financial statements.
Read full article »
Sigilon is a Massachusetts-based biopharmaceutical company that researches and develops cell therapies for the treatment of chronic diseases.
Read more